The goal of this prospective interventional study is to improve the detection of subclinical chronic Cancer Therapy-Related Cardiovascular Toxicity (CTRCT) and evaluate the added value of advanced cardioechography, ergospirometry, and specific biomarkers in pediatric cancer survivors (aged 2 to 25) who received potentially cardiotoxic treatments (chemotherapy/thoracic radiotherapy). The main questions it aims to answer are: * Can advanced echocardiography (including strain and myocardial work), ECG, and ergospirometry effectively diagnose earlier subclinical cardiac impairment in this population? * What is the prevalence of cardiovascular risk factors (including physical activity levels and biological markers like proBNP/troponins) * Can new genetic or biological markers be identified to help optimizing the detection of CTRCT? At time of follow-up, if they agree, participants will: * Complete validated questionnaires regarding quality of life, physical activity, and sedentary behavior. * Undergo a cardiopulmonary exercise test (ergospirometry) for those aged over 8 years. * Wear an accelerometer (ActiGraph GT3X) for 7 consecutive days to monitor physical activity. * Provide an additional blood sample during routine follow-up for the creation of a biobank dedicated to analyzing markers of senescence, fibrosis, apoptosis, and genetic polymorphisms.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
100
Completion of validated, age-appropriate quality of life scales and physical activity assessment forms. Patients over 8 years of age will perform a standardized cardiopulmonary exercise test (CPET / ergospirometry) on a treadmill. Seven-day continuous monitoring using a wearable accelerometer. Collection of a 10 mL blood sample (one EDTA tube and one serum-clotting tube), to be centrifuged and stored at -80°C in the CHU de Liège "BHUL" biobank.
EKG anomaly
Presence of arrhythmia, prolonged QTc interval, or conduction disorders.
Time frame: At inclusion (single study visit)
Echocardiography anomaly: systolic dysfunction
Systolic dysfunction: LVEF \< 55% or a relative decrease of \>15%.
Time frame: At inclusion (single study visit)
Echocardiography anomaly: diastolic dysfunction
Based on standardized pediatric values : * E/A ratioaverage * E/e' \> 14 * e' velocities * LA volume index \> 32 mL/m².
Time frame: At inclusion (single study visit)
Echocardiography anomaly: Significant alteration in myocardial deformation
GLS decrease \> 15%
Time frame: At inclusion (single study visit)
Echocardiography anomaly: myocardial work indices
abnormal Myocardial Work indices
Time frame: At inclusion (single study visit)
Echocardiography anomaly: valvular disease or heart inflammation
Structural/Inflammatory damage: Significant valvular disease, or signs of acute/chronic pericarditis and myocarditis.
Time frame: At inclusion (single study visit)
Cardiopulmonary Exercise Testing (CPET): Impaired functional capacity
defined as peak VO2 \< 85% or maximal workload \< 85% of predicted theoretical values.
Time frame: At inclusion (single study visit)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.